Kabata, Hiroki

写真a

Affiliation

School of Medicine, Department of Internal Medicine (Pulmonary Medicine) （Shinanomachi）

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)
Page Top ▲

Other Affiliation 【 Display / hide 】

  • RIKEN center for Integrative Medical Sciences, Laboratory for Innate Immune Systems, Visiting researcher

Page Top ▲

Career 【 Display / hide 】

  • 2006.04
    -
    2008.03

    独立行政法人国立病院機構東京医療センター, 初期研修医

  • 2008.04
    -
    2009.03

    慶應義塾大学医学部, 専修医

  • 2009.04
    -
    2010.03

    川崎市立川崎病院, 総合診療科, 専修医

  • 2011.05
    -
    2014.03

    慶應義塾大学医学部, 内科学, 助教（臨床実習）

  • 2014.04
    -
    2016.04

    川崎市立川崎病院, 呼吸器内科, 副医長

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2000.04
    -
    2006.03

    Keio University, 医学部

    University, Graduated

  • 2010.04
    -
    2014.03

    Keio University, 大学院, 医学研究科

    Graduate School, Graduated, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士(医学), Keio University, Dissertation, 2014.03

    Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本内科学会, 認定医, 2009.09

  • 日本呼吸器学会, 専門医, 2013.12

  • 日本アレルギー学会, 専門医, 2016

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Immunology (ILC2)

  • Life Science / Respiratory medicine (Asthma)

Page Top ▲

Research Keywords 【 Display / hide 】

  • Group 2 innate lymphoid cell, ILC2

  • IL-33

  • TSLP

  • Severe asthma

Page Top ▲
 

Papers 【 Display / hide 】

  • Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells.

    Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K

    Inflammation （Inflammation)  45 （ 4 ） 1765 - 1779 2022.08

    ISSN  0360-3997

    　View Summary

    Chronic obstructive pulmonary disease (COPD) is primarily caused by inhalation of cigarette smoke and is the third leading cause of death worldwide. Pulmonary surfactant, a complex of phospholipids and proteins, plays an essential role in respiration by reducing the surface tension in the alveoli. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is an enzyme that catalyzes the biosynthesis of surfactant lipids and is expressed in type 2 alveolar epithelial cells. Its dysfunction is suggested to be involved in various lung diseases; however, the relationship between LPCAT1 and COPD remains unclear. To investigate the role of LPCAT1 in the pathology of COPD, we analyzed an elastase-induced emphysema model using Lpcat1 knockout (KO) mice. In Lpcat1 KO mice, elastase-induced emphysema was significantly exacerbated with increased apoptotic cells, which was not ameliorated by supplementation with dipalmitoylphosphatidylcholine, which is a major component of the surfactant synthesized by LPCAT1. We subsequently evaluated the effects of cigarette smoking on primary human type 2 alveolar epithelial cells (hAEC2s) and found that cigarette smoke extract (CSE) downregulated the expression of Lpcat1. Furthermore, RNA sequencing analysis revealed that the apoptosis pathway was significantly enriched in CSE-treated primary hAEC2s. Finally, we downregulated the expression of Lpcat1 using small interfering RNA, which resulted in enhanced CSE-induced apoptosis in A549 cells. Taken together, cigarette smoke–induced downregulation of LPCAT1 can promote the exacerbation of pulmonary emphysema by increasing the susceptibility of alveolar epithelial cells to apoptosis, thereby suggesting that Lpcat1 is a novel therapeutic target for irreversible emphysema.

  • Young woman with multiple lung nodules: a pulmonary oxymoron.

    Tanaka H, Kabata H, Emoto K, Hayashi S, Masai K, Fukunaga K

    Thorax  2022.07

    ISSN  0040-6376

  • One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis.

    Watanabe A, So M, Iwagami M, Fukunaga K, Takagi H, Kabata H, Kuno T

    Respirology (Carlton, Vic.) （Respirology)  27 （ 8 ） 605 - 616 2022.06

    ISSN  1323-7799

    　View Summary

    Coronavirus disease 2019 (COVID-19) often causes radiological and functional pulmonary sequelae. However, evidence on 1-year follow-up of pulmonary sequelae is limited. We aimed to investigate the characteristics and time-course of pulmonary sequelae after recovery from COVID-19 through 1-year follow-up. We searched PubMed and EMBASE databases on 25 February 2022, and included studies with computed tomography (CT) findings at the 1-year follow-up. The extracted data on CT findings were analysed using a one-group meta-analysis. We further analysed the data in relation to COVID-19 severity, improvement rate and lung function. Fifteen eligible studies (N = 3134) were included. One year after COVID-19, 32.6% (95% CI 24.0–42.6, I2 = 92.9%) presented with residual CT abnormalities. Ground-glass opacity and fibrotic-like changes were frequently observed in 21.2% (95% CI 15.4–28.4, I2 = 86.7%) and 20.6% (95% CI 11.0–35.2, I2 = 91.9%), respectively. While the gradual recovery was seen on CT (52.9% [mid-term] vs. 32.6% [1 year]), the frequency of CT abnormalities was higher in the severe/critical cases than in the mild/moderate cases (37.7% vs. 20.7%). In particular, fibrotic changes showed little improvement between 4–7 months and 1 year after COVID-19. Pulmonary function tests at 1 year also showed the decline in diffusing capacity of the lung for carbon monoxide, especially in severe/critical cases. Our meta-analysis indicated that residual CT abnormalities were common in hospitalized COVID-19 patients 1 year after recovery, especially fibrotic changes in severe/critical cases. As these sequelae may last long, vigilant observations and longer follow-up periods are warranted.

  • An Inhalation Device With Inertial Measurement Unit for Monitoring Inhaler Technique

    Takano Shunya, Shimono Tomoyuki, Masaki Katsunori, Fukunaga Koichi, Kabata Hiroki, Nishie Miyuki, Ezaki Taiko, Nakada Hideo, Hakamata Jun, Hasegawa Atsushi

    IEEE-ASME TRANSACTIONS ON MECHATRONICS （IEEE/ASME Transactions on Mechatronics)   2022.06

    ISSN  1083-4435

    　View Summary

    Inhalers are commonly used to treat asthma and chronic obstructive pulmonary disease. Regular and correct usage of inhalers is necessary for effective use. However, approximately 70% of patients do not use their inhalers as directed. This is due to a lack of understanding about the medication and misunderstanding of directions. Assessment of patients’ inhaler techniques are usually conducted in person. However, doctors or pharmacists have no objective information regarding how patients use their inhalers at home. Therefore, monitoring daily inhaler use is necessary for precise medical treatment. This article proposes an inhalation monitoring device using an inertial measurement unit (IMU). The IMU is used to measure a patient’s inhalation motion. Incorrect inhalation usage can be determined by comparing the measurement data against data that indicate correct usage. The experimental results show the utility of the proposed device.

  • Early intubation and decreased in-hospital mortality in patients with coronavirus disease 2019.

    Yamamoto R, Kaito D, Homma K, Endo A, Tagami T, Suzuki M, Umetani N, Yagi M, Nashiki E, Suhara T, Nagata H, Kabata H, Fukunaga K, Yamakawa K, Hayakawa M, Ogura T, Hirayama A, Yasunaga H, Sasaki J, J-RECOVER study group.

    Critical care (London, England) （Critical Care)  26 （ 1 ） 124 2022.05

    ISSN  1364-8535

    　View Summary

    Background: Some academic organizations recommended that physicians intubate patients with COVID-19 with a relatively lower threshold of oxygen usage particularly in the early phase of pandemic. We aimed to elucidate whether early intubation is associated with decreased in-hospital mortality among patients with novel coronavirus disease 2019 (COVID-19) who required intubation. Methods: A multicenter, retrospective, observational study was conducted at 66 hospitals in Japan where patients with moderate-to-severe COVID-19 were treated between January and September 2020. Patients who were diagnosed as COVID-19 with a positive reverse-transcription polymerase chain reaction test and intubated during admission were included. Early intubation was defined as intubation conducted in the setting of ≤ 6 L/min of oxygen usage. In-hospital mortality was compared between patients with early and non-early intubation. Inverse probability weighting analyses with propensity scores were performed to adjust patient demographics, comorbidities, hemodynamic status on admission and time at intubation, medications before intubation, severity of COVID-19, and institution characteristics. Subgroup analyses were conducted on the basis of age, severity of hypoxemia at intubation, and days from admission to intubation. Results: Among 412 patients eligible for the study, 110 underwent early intubation. In-hospital mortality was lower in patients with early intubation than those with non-early intubation (18 [16.4%] vs. 88 [29.1%]; odds ratio, 0.48 [95% confidence interval 0.27–0.84]; p = 0.009, and adjusted odds ratio, 0.28 [95% confidence interval 0.19–0.42]; p < 0.001). The beneficial effects of early intubation were observed regardless of age and severity of hypoxemia at time of intubation; however, early intubation was associated with lower in-hospital mortality only among patients who were intubated later than 2 days after admission. Conclusions: Early intubation in the setting of ≤ 6 L/min of oxygen usage was associated with decreased in-hospital mortality among patients with COVID-19 who required intubation. Trial Registration None.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • アレルギー相談室Q&A　呼吸器内科　アレルギー炎症におけるTSLPの役割

    加畑 宏樹

    アレルギーの臨床 ((株)北隆館)  42 ( 7 ) 523 - 523 2022.07

    ISSN  0285-6379

  • 未開封のパンケーキミックスによるOral mite anaphylaxisの1例

    中原 一帆, 正木 克宜, 岡田 真彦, 松山 笑子, 林 玲奈, 栗原 桃子, 冨保 紗希, 福島 貴大, 加畑 宏樹, 福永 興壱

    アレルギー ((一社)日本アレルギー学会)  71 ( 3 ) 262 - 262 2022.05

    ISSN  0021-4884

  • Tezepelumab(抗TSLP抗体)

    栗原 桃子, 入江 美聡, 加畑 宏樹

    臨床免疫・アレルギー科 ((有)科学評論社)  77 ( 4 ) 486 - 492 2022.04

    ISSN  1881-1930

  • 成人喘息患者における食物アレルギーの合併調査(最終報告)

    冨保 紗希, 正木 克宜, 田野崎 貴絵, 西江 美幸, 渡瀬 麻友子, 松山 笑子, 林 玲奈, 栗原 桃子, 笹原 広太郎, 砂田 啓英也, 浅岡 雅人, 秋山 勇人, 入江 美聡, 加畑 宏樹, 内山 美弥, 各務 恵理菜, 花井 彰剛, 野尻 哲也, 福永 興壱

    日本呼吸器学会誌 ((一社)日本呼吸器学会)  11 ( 増刊 ) 197 - 197 2022.04

    ISSN  2186-5876

  • 慣性計測センサ取得データのDynamic programmingマッチングを用いた吸入動作正誤判定

    西江 美幸, 正木 克宜, 中田 英夫, 林 玲奈, 袴田 潤, 松山 笑子, 栗原 桃子, 砂田 啓英也, 秋山 勇人, 入江 美聡, 田野崎 貴絵, 加畑 宏樹, 長谷川 敦司, 高野 俊也, 下野 誠通, 青森 達, 福永 興壱

    日本呼吸器学会誌 ((一社)日本呼吸器学会)  11 ( 増刊 ) 294 - 294 2022.04

    ISSN  2186-5876

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Novel therapeutic strategy for refractory asthma using immunophenotyping

    2022.04
    -
    2025.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), No Setting

    　View Summary

    喘息は我が国において成人120万人が治療を受けている病気であるが、そのうちの5-10％が喘息治療に不応性の難治性喘息言が存在すると言われている。これら治療に難渋する喘息に対して近年使用できるようになった生物学的製剤が有効であるが、その使用選択にあたってはいまだ確立された方法がない。そこで我々は難治性喘息患者の血液細胞（リンパ球など）を用いて、治療効果を予測できるシステムを1細胞分泌時間イメージング法（LCI-S)と言う新たなシステムを使いながら確立することを目的とする。

  • 気管支喘息及び慢性副鼻腔炎における高病原性ILC2を標的とした新規制御因子の探索

    2022.04
    -
    2025.03

    Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), No Setting

    　View Summary

    ILC2の多様性を詳細に解析することにより、ILC2の有益な機能は温存しつつ、過剰な活性化や2型サイトカインを産生するILC2のみを抑制するような理想的な抑制因子が同定できる可能性がある。このような高病原性のILC2を特異的に抑制する因子は、気管支喘息やアレルギー疾患に対するより優れた治療ターゲットになると考えられる。

  • JRS Asthma Research Program A

    2022.04
    -
    2022.09

    Research grant, Principal investigator

  • Mochida Memorial Foundation for Medical and Pharmaceutical Research

    2021.10
    -
    2022.12

    Research grant, Principal investigator

  • ILC2をターゲットとした新規抑制化合物・天然物の同定

    2020.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists , Principal investigator

    　View Summary

    近年、既に臨床で用いられている薬剤の中から本来の薬効とは異なる作用を見つけ、別の疾患の治療薬としての適応を探索する既存薬スクリーニング(Drug repositioning, DR)研究が注目を集めている。本研究では、気管支喘息やアレルギー性疾患に関与する2型自然リンパ球を抑制する新しい物質を調査し、気管支喘息やアレルギー性疾患に対する治療候補物質の検討を行う。

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2024

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2023

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2022

  • 薬理学

    2021, Lecture

  • LECTURE SERIES, INTERNAL MEDICINE (PULMONOLOGY)

    2021

display all >>

Page Top ▲